Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Bristol Myers Squibb Co.    BMY   US1101221083

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 

U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH

06/25/2012| 08:58am US/Eastern
Recommend:
0

Among the companies with shares expected to actively trade in Monday's session are Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.), Pfizer Inc. (>> Pfizer Inc.) and Momenta Pharmaceuticals Inc. (>> Momenta Pharmaceuticals, Inc.).

Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) and Pfizer Inc. (>> Pfizer Inc.) said the U.S. Food and Drug Administration has requested more information on their anti-clotting drug Eliquis. The request pushes back the potential for U.S. sales of the drug, which is already approved in Europe. Shares of the smaller Bristol-Myers dropped 4.6% to $33.75 in premarket trading while Pfizer shares were last trading down 2.3% to $22.21.

Teva Pharmaceutical Industries Ltd. (TEVA) said a U.S. district court validated its patents for the multiple-sclerosis drug Copaxone and found purported generic versions by Mylan Inc. (>> Mylan Inc.) and Momenta Pharmaceuticals Inc. (>> Momenta Pharmaceuticals, Inc.) infringe those patents. The news lifted Teva shares 7% to $40.70 premarket, while sending Momenta shares plunging 21% to $13.50 premarket. Shares of the larger Mylan were trading slightly lower at $21.10.

Ventrus Biosciences Inc.'s (VTUS) hemorrhoidal disease treatment iferanserin failed to meet primary endpoints in a Phase 3 trial. Shares of the development-stage pharmaceutical plunged plunged 57% to $5.21 premarket as it said it has no immediate plans to continue the drug's development.

Lexicon Pharmaceuticals Inc. (>> Lexicon Pharmaceuticals, Inc.) said a study showed the combined use of its LX4211 with the established diabetes therapy metformin reduced the amount of glucose in patients with poorly controlled type 2 diabetes. Shares jumped 14% to $2.17 premarket.

Watchlist:

Moody's Investors Service raised its ratings on Dillard's Inc. (>> Dillard's, Inc.) one notch closer to investment grade, citing the department-store operator's continued strong operating performance.

Restaurant operator J. Alexander's Corp. (>> J. Alexander's Corporation) agreed to be acquired by a unit of insurer Fidelity National Financial Inc. (>> Fidelity National Financial Inc) in a cash-and-stock deal that values it at roughly $72 million.

Kirby Corp. (>> Kirby Corporation) lowered its second-quarter and full-year earnings estimates, noting softness in its land-based diesel engine services business.

Analysts at Goldman Sachs upgraded SanDisk Corp. (>> SanDisk Corporation) to buy from neutral, saying current oversupply conditions should ease by the fourth quarter, helping the data-storage company to see better margins.

St. Jude said late Friday that it has identified a single Durata defibrillator lead that was damaged due to an external abrasion, but said the lead did not have the critical flaw of an earlier version of the device that St. Jude no longer sells.

-Write to Mia Lamar at mia.lamar@dowjones.com

Recommend :
0
Partner Area
React to this article
 
Latest news on BRISTOL MYERS SQUIBB CO.
3d ago BRISTOL MYERS SQUIBB CO.: Bristol-Myers Squibb Announces Intention to Voluntari..
4d agoDJPair of Studies Show Power of Immune System to Fight Cancer
4d ago BRISTOL MYERS SQUIBB CO.: Bristol-Myers Squibb to Hold Investor Teleconference ..
4d ago BRISTOL MYERS SQUIBB CO.: Bristol-Myers Squibb Advances Leadership Position in ..
5d ago BRISTOL MYERS SQUIBB CO.: Bristol-Myers Squibb to Present at UBS Global Health ..
5d ago BRISTOL MYERS SQUIBB CO.: EmergingGrowth.com looks at Small Cap Specialty Pharm..
05/10DJAbbVie Chief Scientific Officer John Leonard to Retire
05/08 BRISTOL MYERS SQUIBB CO.: Bristol-Myers Squibb to Present at Bank of America Me..
05/06DJAbbVie's Investigational Hepatitis C Virus Regimen Gets Breakthrough-Therapy ..
05/06DJU.S. HOT STOCK FUTURES: Hot stocks to watch
Advertisement
Chart
Duration : Period :
Bristol Myers Squibb Co. Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Income Statement Evolution
Bristol Myers Squibb Co. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.